Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

Published:2013-03-21 Issue:8 Volume:27 Page:1738-1744
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Rajkumar S V,Gupta V,Fonseca R,Dispenzieri A,Gonsalves W I,Larson D,Ketterling R P,Lust J A,Kyle R A,Kumar S K

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201386.pdf

Reference44 articles.

1. Rajkumar SV . Treatment of multiple myeloma. Nature Rev Clin Oncol 2011; 8: 479–491.

2. Rajkumar SV . Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 225–235.

3. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149–157.

4. Sinha S, Lacy M, Mikhael J, Hayman S, Buadi F, Detweiler-Short K et al. Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. Leukemia 2012; 26: 839–841.

5. Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M . Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Leukemia 2012; 26: 73–85.

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TRIM44, a Novel Prognostic Marker, Supports the Survival of Proteasome-Resistant Multiple Myeloma Cells;Cells;2024-08-26

2. How to Identify and Manage High-Risk Smoldering Multiple Myeloma;Current Oncology Reports;2024-08-23

3. Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions;Pharmaceuticals;2024-07-06

4. Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-06-28

5. Still high risk? A review of translocation t(14;16) in multiple myeloma;American Journal of Hematology;2024-06-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3